Randomized trial comparing telephone versus in-person weight loss counseling on body composition and circulating biomarkers in women treated for breast cancer: the Lifestyle, Exercise, and Nutrition (LEAN) study. Harrigan M, Cartmel B, Loftfield E, Sanft T, Chagpar AB, Zhou Y, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. 2006 176:520–5.Īlibhai SM, Breunis H, Timilshina N, Johnston C, Tomlinson G, Tannock I, et al. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. Yannucci J, Manola J, Garnick MB, Bhat G, Bubley GJ. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. 2012 30:3271–6.īraga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, et al. Sarcopenia during androgen-deprivation therapy for prostate cancer. Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TL, Ke C, et al. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer.
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. 1997 337:295–300.ĭ’Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. Bethesda, Maryland: US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute 2020.īolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. Cancer Statistics Data Visualizations Tool, based on 2019 submission data (1999-2017).
This study provides strong preliminary data to develop future clinical trials in this population. ConclusionĬLIPP demonstrates feasibility and early efficacy of a multicomponent lifestyle modification intervention toward addressing obesity as well as components of metabolic syndrome in men on ADT for prostate cancer.
Statistically significant improvements were noted between baseline and end of study measurements for weight (206.3 vs. Recruitment, retention, and adherence rates were 47.1%, 90.3%, and 100%, respectively. Weight and components of metabolic syndrome (waist circumference, triglycerides (TG), high-density lipoprotein (HDL), serum glucose, and blood pressure (BP)) were measured at baseline, 12, and 24 weeks. Feasibility was determined by calculating study recruitment, retention, and adherence rates. This was followed by 8 weeks of passive follow-up resulting in a total trial duration of 24 weeks. A multicomponent lifestyle modification program was delivered weekly for 16 weeks by a trained health coach. MethodsĪ single-arm, open-label clinical trial was conducted by recruiting 31 men diagnosed with prostate cancer and exposed to ADT within the last 5 years. The Comprehensive Lifestyle Improvement Program for Prostate Cancer (CLIPP) was created to determine the feasibility of conducing a comprehensive lifestyle modification intervention in men on ADT for prostate cancer and determine its early efficacy in reducing obesity and metabolic syndrome. Androgen deprivation therapy (ADT) for prostate cancer is associated with adverse effects, such as obesity and metabolic syndrome, which increase cardiovascular risk, the most common cause of non-cancer mortality in men diagnosed with prostate cancer.